Danish biotech company Evaxion (Nasdaq: EVAX) has announced initial results from a Phase II trial of the first five metastatic melanoma patients treated with EVX-01, a peptide-based personalized cancer vaccine.
Shares in Evaxion jumped up by 18% during Tuesday morning’s trading following the announcement.
This study is a self-sponsored open-label, single-arm, multicenter trial carried out in collaboration with US pharma giant Merck & Co (NYSE: MRK), and together with leading principal investigators and research centers from Italy and Australia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze